A. Aghokeng

发表

Gender Differences in Adherence and Response to Antiretroviral Treatment in the Stratall Trial in Rural District Hospitals in Cameroon

E. Delaporte, M. Carrieri, B. Spire, 2015, Journal of acquired immune deficiency syndromes.

Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia.

M. Peeters, E. Delaporte, S. Eymard-Duvernay, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Task Shifting HIV Care in Rural District Hospitals in Cameroon: Evidence of Comparable Antiretroviral Treatment-Related Outcomes Between Nurses and Physicians in the Stratall ANRS/ESTHER Trial

E. Delaporte, M. Carrieri, B. Spire, 2013, Journal of acquired immune deficiency syndromes.

Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial.

E. Delaporte, M. Carrieri, B. Spire, 2011, The Lancet. Infectious diseases.

Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa

A. Diouf, M. Peeters, E. Delaporte, 2019, PharmacoEconomics - Open.

WHO clinical criteria–based initiation of antiretroviral therapy: lessons from rural district hospitals in Cameroon with regard to 2009 revised WHO recommendations

E. Delaporte, C. Laurent, C. Kouanfack, 2010, Tropical medicine & international health : TM & IH.

Prevalence of pretreatment HIV drug resistance in West African and Southeast Asian countries

V. Calvez, F. Brun-Vézinet, M. Peeters, 2018, The Journal of antimicrobial chemotherapy.

High rate of virological failure and HIV drug resistance in semi-rural Gabon and implications for dolutegravir-based regimen efficacy.

A. Mouinga-Ondémé, A. Aghokeng, S. LEKANA-DOUKI, 2020, The Journal of antimicrobial chemotherapy.

Prevalence of pretreatment HIV drug resistance in Cameroon following a nationally representative WHO survey

S. Eymard-Duvernay, Suzanne Izard, C. Kouanfack, 2018, The Journal of antimicrobial chemotherapy.

Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon

E. Delaporte, M. Carrieri, B. Spire, 2014, HIV medicine.

Trend of expansion of SARS-CoV-2 infection and COVID-19 burden in Gabon (Central Africa) in mid-2021, based on a serological survey

E. Elguero, A. Aghokeng, J. Nzenze, 2022, IJID Regions.

SARS-CoV-2 antibodies prevalence in the Republic of Congo in mid-2021

E. Elguero, F. Koukouikila-Koussounda, A. Aghokeng, 2022, IJID Regions.

Declining trends in early warning indicators for HIV drug resistance in Cameroon from 2008–2010: lessons and challenges for low-resource settings

V. Colizzi, P. Ndumbe, S. Billong, 2013, BMC Public Health.

Lamivudine-Resistant HBV Infection in HIV-Positive Patients Receiving Antiretroviral Therapy in a Public Routine Clinic in Cameroon

E. Delaporte, C. Laurent, J. Ducos, 2012, Antiviral therapy.

Prevalence of SARS-CoV-2 antibodies in the Republic of Congo in mid-2021

E. Elguero, F. Koukouikila-Koussounda, A. Aghokeng, 2022, IJID Regions.

Enfuvirtide binding domain is highly conserved in non-B HIV type 1 strains from Cameroon, West Central Africa.

M. Peeters, E. Delaporte, L. Zekeng, 2005, AIDS research and human retroviruses.

Field Evaluation of Dried Blood Spots for Routine HIV-1 Viral Load and Drug Resistance Monitoring in Patients Receiving Antiretroviral Therapy in Africa and Asia

M. Peeters, E. Delaporte, S. Eymard-Duvernay, 2013, Journal of Clinical Microbiology.

Prediction of HIV drug resistance based on virologic, immunologic, clinical, and/or adherence criteria in the Stratall ANRS 12110/ESTHER trial in Cameroon.

M. Peeters, E. Delaporte, M. Carrieri, 2013, Clinical Infectious Diseases.

Noninvasive Follow-Up of Simian Immunodeficiency Virus Infection in Wild-Living Nonhabituated Western Lowland Gorillas in Cameroon

M. Peeters, F. Liégeois, E. Delaporte, 2012, Journal of Virology.

Characterization of a new simian immunodeficiency virus strain in a naturally infected Pan troglodytes troglodytes chimpanzee with AIDS related symptoms

M. Lebreton, U. Tamoufé, N. Wolfe, 2011, Retrovirology.

Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

Huldrych F. Günthard, Tulio de Oliveira, Lynn Morris, 2016 .

Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months’ antiretroviral therapy experience in Cameroon

M. Peeters, E. Delaporte, S. Eymard-Duvernay, 2013, Journal of the International AIDS Society.

Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries

M. Peeters, E. Delaporte, L. Vergne, 2008, Antiviral therapy.

HIV-1 Drug-Resistance Mutations among Newly Diagnosed Patients before Scaling-Up Programmes in Burkina Faso and Cameroon

M. Peeters, E. Delaporte, C. Laurent, 2005, Antiviral therapy.

HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis

Tulio de Oliveira, Meg Doherty, Deenan Pillay, 2017, The Lancet. Infectious diseases.

Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.

E. Delaporte, J. Moatti, M. Carrieri, 2013, The Lancet. Infectious diseases.

Failure to Detect Simian Immunodeficiency Virus Infection in a Large Cameroonian Cohort with High Non-human Primate Exposure

D. Burke, M. Lebreton, B. S. Schneider, 2012, EcoHealth.

HIV-1 group O infection in Cameroon from 2006 to 2013: Prevalence, genetic diversity, evolution and public health challenges.

M. Peeters, E. Delaporte, C. Villabona-Arenas, 2015, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Extensive survey on the prevalence and genetic diversity of SIVs in primate bushmeat provides insights into risks for potential new cross-species transmissions.

M. Peeters, F. Liégeois, Severin Loul, 2010, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Molecular characterization of a novel simian immunodeficiency virus lineage (SIVtal) from northern talapoins (Miopithecus ogouensis).

M. Peeters, F. Liégeois, Severin Loul, 2006, Virology.

Widely varying SIV prevalence rates in naturally infected primate species from Cameroon.

G. Shaw, B. Hahn, M. Peeters, 2006, Virology.

Inaccurate Diagnosis of HIV-1 Group M and O Is a Key Challenge for Ongoing Universal Access to Antiretroviral Treatment and HIV Prevention in Cameroon

M. Peeters, E. Delaporte, A. Aghokeng, 2009, PloS one.

Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis

Jerome H. Kim, J. Ioannidis, D. Katzenstein, 2015, PLoS Medicine.

High Failure Rate of the ViroSeq HIV-1 Genotyping System for Drug Resistance Testing in Cameroon, a Country with Broad HIV-1 Genetic Diversity

M. Peeters, E. Delaporte, A. Aghokeng, 2011, Journal of Clinical Microbiology.

HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing

T. F. Rinke de Wit, D. Katzenstein, R. Shafer, 2015, PloS one.

Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.

D. Katzenstein, N. Ford, R. Shafer, 2013, The Journal of infectious diseases.

Rate of virological failure and HIV-1 drug resistance among HIV-infected adolescents in routine follow-up on health facilities in Cameroon

C. E. Eboumbou Moukoko, J. Fokam, A. Ndjolo, 2022, PloS one.

Nationwide Estimates of Viral Load Suppression and Acquired HIV Drug Resistance in Cameroon

S. Eymard-Duvernay, A. Cournil, A. Aghokeng, 2018, EClinicalMedicine.

Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis

Jerome H. Kim, J. Ioannidis, D. Katzenstein, 2015, PLoS medicine.

Population-Based Monitoring of Emerging HIV-1 Drug Resistance on Antiretroviral Therapy and Associated Factors in a Sentinel Site in Cameroon: Low Levels of Resistance but Poor Programmatic Performance

V. Colizzi, S. Billong, J. Fokam, 2013, PloS one.

Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients

Christian Laurent, Martine Peeters, M. Peeters, 2011, AIDS.

Short Communication: High Viral Load and Multidrug Resistance Due to Late Switch to Second-Line Regimens Could Be a Major Obstacle to Reach the 90-90-90 UNAIDS Objectives in Sub-Saharan Africa.

M. Peeters, E. Delaporte, S. Eymard-Duvernay, 2016, AIDS research and human retroviruses.

Tenofovir resistance in early and long-term treated patients on first-line antiretroviral therapy in eight low- and middle-income countries.

S. Ávila-Ríos, S. Billong, D. Ssemwanga, 2020, AIDS.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Virologic Failure and Human Immunodeficiency Virus Drug Resistance in Rural Cameroon With Regard to the UNAIDS 90-90-90 Treatment Targets

M. Peeters, E. Delaporte, C. Laurent, 2016, Open forum infectious diseases.

Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from Burkina Faso, Côte d'Ivoire, Senegal, Thailand, and Vietnam: the ANRS 12134 study.

M. Peeters, E. Delaporte, D. Costagliola, 2009, AIDS research and human retroviruses.

Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.

M. Peeters, E. Delaporte, S. Eymard-Duvernay, 2017, The lancet. HIV.

Field evaluation of an open and polyvalent universal HIV-1/SIVcpz/SIVgor quantitative RT-PCR assay for HIV-1 viral load monitoring in comparison to Abbott RealTime HIV-1 in Cameroon.

M. Peeters, E. Delaporte, S. Eymard-Duvernay, 2016, Journal of virological methods.

Demographic and Clinical Characteristics Associated With Severity, Clinical Outcomes, and Mortality of COVID-19 Infection in Gabon

P. Pineau, A. Mouinga-Ondémé, Judicaël Obame-Nkoghe, 2021, JAMA network open.

Full-length sequence analysis of SIVmus in wild populations of mustached monkeys (Cercopithecus cephus) from Cameroon provides evidence for two co-circulating SIVmus lineages.

P. Sharp, M. Peeters, E. Bailes, 2007, Virology.

Phyloepidemiological Analysis Reveals that Viral Divergence Led to the Paucity of Simian Immunodeficiency Virus SIVmus/gsn/mon Infections in Wild Populations

M. Lebreton, U. Tamoufé, J. Diffo, 2017, Journal of Virology.

Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients.

A. Vandamme, M. Peeters, E. Delaporte, 2006, FEMS immunology and medical microbiology.

Susceptibility to Transmitting HIV in Patients Initiating Antiretroviral Therapy in Rural District Hospitals in Cameroon (Stratall ANRS 12110/ESTHER Trial)

M. Peeters, E. Delaporte, J. Moatti, 2013, PloS one.

Time Patterns of Adherence and Long-Term Virological Response to Non-Nucleoside Reverse Transcriptase Inhibitor Regimens in the Stratall Anrs 12110/Esther Trial in Cameroon

E. Delaporte, J. Moatti, M. Carrieri, 2013, Antiviral therapy.

Evaluation of Four Simple/Rapid Assays and Two Fourth-Generation FLISAs for the Identification of HIV Infection on a Serum Panel Representing the HIV-1 Group M Genetic Diversity in Cameroon

Martine Peeters, M. Peeters, E. Delaporte, 2004, Journal of acquired immune deficiency syndromes.

Drug resistance mutations of HIV type 1 non-B viruses to integrase inhibitors in treatment-naive patients from sub-saharan countries and discordant interpretations.

M. Peeters, M. Chaix, A. Aghokeng, 2012, AIDS research and human retroviruses.

Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment.

M. Peeters, E. Delaporte, C. Laurent, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Comparative immuno-virological and clinical responses to antiretroviral therapy between HIV-1 group O- and HIV-1 group M-infected patients (ANRS 12168 DynaMO study).

E. Delaporte, J. Dumortier, D. Rousset, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Successful integrase inhibitor-based highly active antiretroviral therapy for a multidrug-class-resistant HIV type 1 group O-infected patient in Cameroon.

M. Peeters, E. Delaporte, C. Kouanfack, 2013, AIDS research and human retroviruses.

Short Communication: Nucleoside Reverse Transcriptase Inhibitors with Reduced Predicted Activity Do Not Impair Second-Line Therapy with Lopinavir/Ritonavir or Darunavir/Ritonavir.

M. Peeters, E. Delaporte, S. Eymard-Duvernay, 2018, AIDS research and human retroviruses.

Genetic diversity among human immunodeficiency virus-1 non-B subtypes in viral load and drug resistance assays.

M. Peeters, E. Delaporte, A. Aghokeng, 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

HIV Drug Resistance in Resource-limited Countries: Threat for HIV Elimination

A. Aghokeng, N. Ngo-Giang-Huong, 2019, EClinicalMedicine.

Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance

Jerome H. Kim, M. Poljak, R. Shafer, 2015 .

Single Real-Time Reverse Transcription-PCR Assay for Detection and Quantification of Genetically Diverse HIV-1, SIVcpz, and SIVgor Strains

M. Peeters, S. Eymard-Duvernay, Lucie Etienne, 2012, Journal of Clinical Microbiology.

Genotyping and antifungal susceptibility testing of Cryptococcus neoformans isolates from Cameroonian HIV-positive adult patients.

E. Delaporte, M. Mallié, S. Bertout, 2013, Clinical Microbiology and Infection.

Single real-time RT-PCR assay for the detection and quantification of 1 genetically diverse HIV-1 , SIVcpz and SIVgor viruses

M. Peeters, S. Eymard-Duvernay, Lucie Etienne, 2012 .

Genetic diversity of simian lentivirus in wild De Brazza’s monkeys (Cercopithecus neglectus) in Equatorial Africa

M. Peeters, E. Delaporte, J. Muyembe, 2010, The Journal of general virology.

Simian immunodeficiency viruses (SIVs) in Africa.

M. Peeters, A. Aghokeng, 2005, Journal of Neurovirology.

Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

Domenico Di Carlo, P. A. Bester, R. Shafer, 2022 .

Viral load suppression in HIV-infected adolescents in cameroon: towards achieving the UNAIDS 95% viral suppression target

Y. Madec, A. Aghokeng, C. Penda, 2023, BMC Pediatrics.

M. Peeters, E. Delaporte, S. Eymard-Duvernay, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Challenges of antiretroviral treatment monitoring in rural and remote-access regions in Africa.

M. Peeters, E. Delaporte, S. Eymard-Duvernay, 2014, AIDS research and human retroviruses.

Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients

M. Peeters, E. Delaporte, C. Laurent, 2011, AIDS.